Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 5
2007 12
2008 15
2009 11
2010 9
2011 8
2012 4
2013 7
2014 3
2015 3
2016 3
2017 4
2018 1
2019 1
2020 5
2021 3
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Carisbamate (RWJ-333369).
Novak GP, Kelley M, Zannikos P, Klein B. Novak GP, et al. Neurotherapeutics. 2007 Jan;4(1):106-9. doi: 10.1016/j.nurt.2006.11.016. Neurotherapeutics. 2007. PMID: 17199023 Free PMC article. Review.
Carisbamate (RWJ-333369) is a novel neuromodulator, initially developed by SK Biopharmaceuticals (Fairlawn, NJ), under development by Johnson & Johnson Pharmaceutical Research and Development (La Jolla, CA). Carisbamate displays high potency in a b …
Carisbamate (RWJ-333369) is a novel neuromodulator, initially developed by SK Biopharmaceuticals (Fairlawn, NJ), under …
Current and future pharmacotherapy options for drug-resistant epilepsy.
Elkommos S, Mula M. Elkommos S, et al. Expert Opin Pharmacother. 2022 Dec;23(18):2023-2034. doi: 10.1080/14656566.2022.2128670. Epub 2022 Sep 27. Expert Opin Pharmacother. 2022. PMID: 36154780 Review.
Many compounds are under clinical development and may hold promise for future pharmacotherapies. For adult focal epilepsies, padsevonil and carisbamate are at a more advanced Phase III stage of clinical development followed by compounds at Phase II like selurampanel, XEN11 …
Many compounds are under clinical development and may hold promise for future pharmacotherapies. For adult focal epilepsies, padsevonil and …
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies.
Strzelczyk A, Schubert-Bast S. Strzelczyk A, et al. CNS Drugs. 2021 Jan;35(1):61-83. doi: 10.1007/s40263-020-00784-8. Epub 2021 Jan 21. CNS Drugs. 2021. PMID: 33479851 Free PMC article. Review.
Other treatments in clinical development include fenfluramine in late phase III, perampanel, soticlestat-OV953/TAK-953, carisbamate and ganaxolone. Non-pharmacologic interventions include the ketogenic diet, vagus nerve stimulation and surgical interventions; these are als …
Other treatments in clinical development include fenfluramine in late phase III, perampanel, soticlestat-OV953/TAK-953, carisbamate a …
Carisbamate (RWJ-333369) inhibits glutamate transmission in the granule cell of the dentate gyrus.
Lee CY, Lee ML, Shih CC, Liou HH. Lee CY, et al. Neuropharmacology. 2011 Dec;61(8):1239-47. doi: 10.1016/j.neuropharm.2011.07.022. Epub 2011 Jul 30. Neuropharmacology. 2011. PMID: 21824485
Carisbamate (CRS, RWJ-333369) is a novel antiepileptic drug awaiting approval for use in the treatment of partial and generalized seizures. ...
Carisbamate (CRS, RWJ-333369) is a novel antiepileptic drug awaiting approval for use in the treatment of partial and g …
Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects.
Zannikos P, Novak G, Yao C, Verhaeghe T, Franc MA, Solanki B, Bialer M. Zannikos P, et al. Epilepsia. 2009 Aug;50(8):1850-9. doi: 10.1111/j.1528-1167.2009.02081.x. Epub 2009 May 11. Epilepsia. 2009. PMID: 19453703 Free article.
PURPOSE: To compare the pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western adults, and to comparatively assess carisbamate safety and tolerability between the two populations. METHODS: An open-label study was conducted in 24 J …
PURPOSE: To compare the pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western adults, and to com …
The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons.
Deshpande LS, Nagarkatti N, Sombati S, DeLorenzo RJ. Deshpande LS, et al. Epilepsy Res. 2008 May;79(2-3):158-65. doi: 10.1016/j.eplepsyres.2008.01.002. Epub 2008 Mar 18. Epilepsy Res. 2008. PMID: 18353614 Free PMC article.
This study was initiated to investigate effects of the novel neuromodulator carisbamate (RWJ 333369) in the hippocampal neuronal culture model of status epilepticus and spontaneous epileptiform discharges. ...All these effects of carisbamate were rever …
This study was initiated to investigate effects of the novel neuromodulator carisbamate (RWJ 333369) in the hippocampal …
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Lu C, Zheng J, Cao Y, Bresnahan R, Martin-McGill KJ. Lu C, et al. Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD012121. doi: 10.1002/14651858.CD012121.pub2. Cochrane Database Syst Rev. 2021. PMID: 34870321 Free PMC article. Review.
Carisbamate may be useful for drug-resistant focal epilepsy. OBJECTIVES: To evaluate the efficacy and tolerability of carisbamate when used as an add-on therapy for drug-resistant focal epilepsy. ...SELECTION CRITERIA: Double-blind randomised controlled trials (RCTs …
Carisbamate may be useful for drug-resistant focal epilepsy. OBJECTIVES: To evaluate the efficacy and tolerability of carisbamate …
An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid.
Chien S, Yao C, Mertens A, Verhaeghe T, Solanki B, Doose DR, Novak G, Bialer M. Chien S, et al. Epilepsia. 2007 Jul;48(7):1328-38. doi: 10.1111/j.1528-1167.2007.01037.x. Epub 2007 Mar 22. Epilepsia. 2007. PMID: 17381436 Free article.
PURPOSE: To characterize possible pharmacokinetic interactions between the new antiepileptic drug carisbamate (RWJ-333369) and valproic acid (VPA) or lamotrigine (LTG) following multiple dosing in healthy subjects. ...CONCLUSIONS: There were no clinically sig …
PURPOSE: To characterize possible pharmacokinetic interactions between the new antiepileptic drug carisbamate (RWJ-333369 …
The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury.
Keck CA, Thompson HJ, Pitkänen A, LeBold DG, Morales DM, Plevy JB, Puri R, Zhao B, Dichter M, McIntosh TK. Keck CA, et al. Restor Neurol Neurosci. 2007;25(2):77-90. Restor Neurol Neurosci. 2007. PMID: 17726266 Free PMC article.
PURPOSE: To evaluate the therapeutic efficacy of two antiepileptic compounds, RWJ-333369 and RWJ-333369-A in a well-established experimental model of lateral fluid percussion (FP) traumatic brain injury (TBI) in the rat. ...RESULTS: In Study I, no impr …
PURPOSE: To evaluate the therapeutic efficacy of two antiepileptic compounds, RWJ-333369 and RWJ-333369-A in a w …
83 results